Aberdeen Group
LTGO

Aberdeen Group’s Latigo Biotherapeutics LTGO Stock Holding History

Aberdeen Group’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.6M Buy
+935,718
New +$19.8M 0.02% 533

Other funds holding LTGO

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Jacobi Capital Management
Jacobi Capital Management Pittston, Pennsylvania $2.11B AUM 19.6% 1-Year Est. Return

Aberdeen Group's LTGO Position: Q3 2026 in Review

Aberdeen Group opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 935,718 shares worth $15.6M. The stake represents 0.02% of the portfolio and ranks #533 among its holdings.

6 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Aberdeen Group held 935,718 shares of Latigo Biotherapeutics worth $15.6M as of Q3 2026.
  • Latigo Biotherapeutics was a new Aberdeen Group position in Q3 2026.
  • Latigo Biotherapeutics made up 0.02% of Aberdeen Group's portfolio in Q3 2026, its #533 holding.
  • 6 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.